Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy
Sign Up to like & getrecommendations! Published in 2017 at "Oncogene"
DOI: 10.1038/onc.2017.1
Abstract: Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the tumor microenvironment.… read more here.
Keywords: bevacizumab; bevacizumab resistant; resistance; mif ... See more keywords
Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0189582
Abstract: Bevacizumab combined with cytotoxic chemotherapy is the backbone of metastatic colorectal cancer (mCRC) therapy; however, its treatment efficacy is hampered by therapeutic resistance. Therefore, understanding the mechanisms underlying bevacizumab resistance is crucial to increasing the… read more here.
Keywords: involved bevacizumab; genes pathways; colorectal cancer; bevacizumab resistant ... See more keywords